SGS Completes Expansion at Mumbai Facility

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-05-06-2015
Volume 11
Issue 5

Stability testing and UPLC capabilities highlight expansion at Mumbai, India facility of SGS Life Science Services.

 

SGS Life Science Services, a clinical and bioanalytical contract solutions provider, has announced the completion of an expansion at its Mumbai, India, facility with validation of new equipment currently underway; an official opening of the laboratory is planned for May 20, 2015.

The expansion has seen the previous 1,393-square meter laboratory space more than double in size, to 3,400 square meters; once validation is completed, the laboratory will act as a dedicated cGMP pharmaceutical testing site. The workforce has increased from 65 to 115, with the potential for up to another 40 employees in the additional facilities, according to a company statement.

Investment at the laboratory focused on increasing stability chamber capacity, and in supporting chromatography equipment, including new UPLC capabilities. The Mumbai facility now has the largest stability testing facility in the SGS Life Science Services’ global network, with the expansion driven by the increased demand from both local and international customers, the company reports.

Three new 100-cubic meter capacity stability chambers have been installed for 21 CFR part 11-compliant short term, long term, and accelerated studies, and covers all the International Conference of Harmonisation (ICH) conditions, as well as flexibility for specific client conditions. The Mumbai expansion follows SGS’s renovation of its Chennai, India, laboratory in 2014, increasing laboratory space within the facility. The number of employees increased from 60 to 75, with the flexibility to further accommodate up to 90.

Source: SGS Life Science Services

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Related Content